Figure S1 from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism

Figure S1. (A) RNA expression and copy number variations in A375 melanoma cell lines resistant to vemurafenib (A375R). RNA expression was normalized according to PPIA, B2M and ACTB gene expression (siRNA: small interfering RNA). (B) Inhibition of CHEK2 at both the mRNA and protein levels in A375 melanoma cell lines resistant to vemurafenib (A375R) transfected with siRNA CHEK2 (50 nM and 100 nM) compared to those transfected with siRNA control (siRNA: small interfering RNA).